Celltrion USA announces availability of adalimumab-aaty with 85% discount
In a bold move to reshape the pharmaceutical landscape, Celltrion USA has announced the availability of its high-concentration, citrate-free biosimilar adalimumab-aaty, under the brand name ... Read More
Celltrion USA launches ZYMFENTRA for ulcerative colitis and Crohn’s disease
In a significant advancement for patients with digestive disorders, Celltrion USA has announced the availability of ZYMFENTRA (infliximab-dyyb), marking it as the first and only ... Read More